Clinical Trials Browser

Ovarian Neoplasms

Ovarian Neoplasms

Gestational Trophoblastic Disease

Endometrial Neoplasms

Carcinoma, Ovarian Epithelial

Ovarian Neoplasms

Ovarian Cancer Recurrent

Ovarian Neoplasms

Uterine Cervical Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms, Triple Negative Breast Neoplasms

Fallopian Tube Neoplasms, Ovarian Neoplasms

Uterine Cervical Neoplasms

Uterine Cervical Neoplasms

Recurrence, Gestational Trophoblastic Disease

Ovarian Neoplasms

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Neoplasms, Ovarian Neoplasms

Ovarian Neoplasms

Sarcoma, Uterine Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms

Uterine Cervical Neoplasms

Ovarian Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

Ovarian Neoplasms

Ovarian Neoplasms, Recurrence

Angiogenesis Inhibitors，Ovarian Neoplasms

Uterine Cervical Neoplasms

Clinical Trials

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

A-CAPE

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

First-line Chemotherapy for Recurrent Cervical Cancer

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

GTN

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.

Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

A Study of Apatinib Treatment in for Advanced Ovarian Cancer

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer